Sources of costs in congestive heart failure
The prevalence and incidence of cardiac failure is high and varies in different areas1. Additionally 1-2% of the population suffer from ventricular dysfunction without overt heart failure. The high mortality of cardiac failure despite optimal therapy prevents an even higher prevalence. Hospitalizations due to cardiac failure are rapidly increasing. The increasing age of the population, the growing prevalence of coronary artery disease and incidence of myocardial infarction in the last decades as well as the high medical efficacy of intensive care medicine lead to a high number of patients leaving intensive care units with massive myocardial damage 2 . Another important contributory factor is the high incidence of progression of heart failure from mild to moderate disease into severe and endstage disease, which constitutes between 10 and 25% of patients per year", Hospitalizations are the major source of outlay in heart failure and especially patients, who become unstable and are repeatedly being hospitalized, utilize health care resources with a much greater intensity. Diagnosis related group prospective hospital payment systems often lead to considerable losses for the hospitals, especially during the prolonged terminal stay of heart failure patients 4 ,5. than a whole spectrum of screening tests followed by a definite test. Once heart failure is established stabilization of the condition even if at considerable cost is much more efficient than proceeding from complication to complication.
Diagnostic work up and pretreatment risk
The most common complaints of patients with congestive heart failure are shortness of breath and fatigue. These constitute quite nonspecific symptoms and therefore have to be further investigated. Analyses of between country differences in the work up of shortness of breath have
GENERAL CONSIDERATIONS
Heart failure is a major cause of morbidity and mortality affecting about 15 million people worldwide, constituting a major health care burden. In patients over 65 years of age it has become one of the most common causes of hospitalization.
Health care payment systems are being restructured worldwide. Health care providers and politicans have turned to utilization controls. In an effort to maintain high quality services despite limited resources they have to focus on cost efficiency rather than just on quality of care alone. While quality of care remains the first prority, the work up and the management including drug therapy of cardiac failure has to consider algorithms, that allow us to provide a maximum of benefit at the lowest possible economic burden.
INTRODUCTION
Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings. We are at the beginning of an era in which waste of resources may be reduced by scientific analysis with improvement in patient care and teaching achieved as a result.
As resources are limited outcome measures have become of increasing importance. Not all diagnostic possibilities, all interventions and any possible drug therapy can be provided to every patient. A decision analysis indicating how to proceed in diagnosis and treatment is mandatory. The diversity of socioeconomic situations, health care, and reimbursement systems do not allow us to extrapolate each local cost efficacy study worldwide. However, certain characteristics of cardiac failure and similarities of care allow the considerations outlined in this article at least to be applied to the industrialized world.
Much more emphasis has to be put on pretest or preinterventional probabilities and diagnostic as well as therapeutic gains of certain applied tools. A straight forward approach towards definitive diagnosis can be much cheaper been performed-and considerable differences in the time elapsing between report of complaints and conclusive diagnosis have been found between teaching practices in the USA and UK. The time until final work up and until institution of adequate therapy might importantly influence the outlay. Thus in the above study fewer visits and fewer consultations led to an earlier diagnosis 6 suggesting improved efficacy. An important step in the work up is the decision when to use costly invasive diagnostic facilities. However, detailed analyses show, that a straightforward approach to diagnosis and treatment might not be more expensive than a long noninvasive work up, in many cases still ending with cardiac catheterization, presumably at a less optimal point of time 7 ,8.
Often patients do not present with typical symptoms and slowly develop heart failure after myocardial infarction. Often they experience an asymptomatic or mildly symptomatic phase of months to a few years. A tremendous amount of literature about treatment of acute myocardial infarction and postmyocardial infarction ventricular dysfunction with various new agents, especially ACE (angiotensin converting enzyme)-inhibitors has been published. Depending on the pretreatment risk of the patients included and the duration of therapy necessary to achieve these goals highly divergent figures for cost effectiveness of ACE-inhibitors were reported". These range between £1500 and £30000 per year of life saved (see Table 1 ). This demonstrates that the pretreatment risk has to be considered, even if the relative reduction in morbidity or mortality by a given drug regimen is similar.
Absolute risk reductions are much easier to understand and to work with, but are often not presented or even obscured by investigators and especially by the pharmaceutical industry. Risk reductions below 1% should be subject to close attention as to whether drug therapy is worthwhile. A risk reduction of 30 relative per cent might also not be worthwhile if, e.g. the reduction is from 2 to 1.4%. It is comparatively unimportant to try to translate the benefits into pecuniary savings. A simple confrontation of benefits and costs in a cost efficiency analysis is often easier to understand than a sophisticated cost benefit calculation.
TREATMENT
The treatment of cardiac failure is usually of superior cost efficacy than prophylaxis of heart failure because savings in terms of hospitalizations are much higher in the symptomatic heart failure population. However, as outlined above, for certain high risks subgroups prophylactic treatment to avoid the development of overt cardiac failure might be relatively cheap and therefore should be promoted.
Various drug treatments have been investigated from an economic perspective. Digoxin has been shown to reduce emergency room visits and hospitalization 10. The withdrawal of digoxin in patients initially responding favourably to digOXin has been shown to be both detrimental to exercise capacityl ' as well as a burden to the economy!", The analysis by Ward12 demonstrates using the example of the RADIANCE and PROVED investigations 11 ,13 that not only the ordering of diagnostiC tests and institution of therapy constitutes a burden, but also that the withdrawal of an effective therapy might cause additional outlay. Thus in the scenario described by Ward'? a nationwide withdrawal of digoxin in heart failure patients would result in an additional outlay between 170 and 870 million US dollars for the USA per year.
Most information relates to the use of vasodilators
Analysis of patient data in the SalVO study!" and extrapolating the findings to the health economy system of Canada demonstrated net savings by administering ACEinhibitors in the range of 574$ per patient over a treatment period of four years, despite costs for enalapril of 1071$. The net savings were due to a reduction in hospitalizations, saving 1645$ per patient over four years-. This benefit was accompanied by two months of average life prolongation per patient.
The comparison of different vasodilators (isosorbidedinitrate plus hydralazine versus enalapril) using data from the SalVO and V-HeFT trials 14,16 resulted in a higher outlay for enalapril as compared to isosorbidedinitrate plus hydralazine (9700 versus 5600 US dollars) but enalapril saved more Iives 17 probably justifying these expenses.
In~Dutch analysis a 10 year forecast of treating congestive heart failure with ACE inhibitors was performed. This analysis showed in agreement with other studies that the savings due to reduction in hospitalizations exceeded the outlay for the treatment'", In the Munich Mild Heart Failure Triap,5 a complete retrospective analysis of 140 patients with heart failure transplantation in endstage heart failure/" and heart transplantation itself. The latter is usually considered to be extremely expensive, but has a favourable cost-effectiveness ratio". The development of artificial hearts should be evaluated in the same context and in comparison with other approaches in endstage heart failure 22 (see Table 3 ).
The management of heart failure patients is extremely important. In the United States nurse practitionars and nurse specialists have taken over some aspects of management. Patient education often massively improves compliance. Self administration or adjustment of drugs is often possible. This plays a role in stabilization of patients and also in determining the need for surgeryB, which is associated with higher outlay in heart failure patients. Poor compliance with diagnostic and therapeutic recommendations may cause much money to be lost. For example, an evaluation of digoxin serum levels found that inappropriate digoxin serum concentrations were often due to inappropriate late drug ingestion before serum level determination/". Simple afternoon administration of digoxin yielded more reliable results and thus was more cost effective. Improvement of outpatient management can lead to savings above and beyond any drug therapy25-n. Correctly tailored therapy including patient education can reduce hospitalizations by 85%28. followed for 1.5 years comprising total costs for diagnosis and treatment of heart failure was performed and the results were extrapolated to the total trial duration (2.7 years) and trial population (n=170). In this analysis, though ACEinhibition doubled the outlay for drug treatment, the reduction in hospitalizations again fully compensated for the additional treatment costs (see Table 2 ). Many patients with heart failure die from sudden death or experience an episode of syncope. More and more patients are successfully resuscitated. Currently no economically balanced analysis of diagnosis and treatment exists. For example, many Holter-ECGs are performed without any therapeutic implication in patients without previous arrhythmias or syncope. On the other hand an early work up and early implantation of automatic implantable defibrillators (AICD) might prevent further costly hospital stays!". Other forms of high technology treatment have to be thoroughly evaluated in economic terms. These include mechanical versus medical bridging therapy before heart 
